Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose.
Rune Labs StriveStudy platform and Emerald Innovations Emerald wireless monitoring sensor will passively capture data on Parkinson s disease impact on.
BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson s Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CAMBRIDGE, Mass., January 18, 2022 – BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in Canada in partnership with the University Health Network in a Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopamine